Loading
A phase 2 trial of Bezuclastinib in systemic mastocytosis, run by Cogent Biosciences, Inc., now recruiting.
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis is a phase 2 interventional study registered as NCT04996875 by Cogent Biosciences, Inc., with 140 participants planned, started 2021-11-09 and due to reach its primary completion in 2025-09-19. Interventions recorded: bezuclastinib. Conditions listed: Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM). No results are recorded here; the registry entry is the source.
Shares Bezuclastinib, Cogent Biosciences, Systemic mastocytosis.
Shares Bezuclastinib, Cogent Biosciences.
Shares Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Systemic mastocytosis.
Shares Bezuclastinib, Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Systemic mastocytosis.
Shares Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Systemic mastocytosis.
Shares Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Systemic mastocytosis.
Shares Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Systemic mastocytosis.
Shares Bezuclastinib, Cogent Biosciences, Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Systemic mastocytosis.